• 1
    Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 212939.
  • 2
    Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011; 3: 75ra26.
  • 3
    Travis WD, Linnoila RI, Tsokos MG et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendoc rine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 1991; 15: 52953.
  • 4
    Morinaga R, Okamoto I, Furuta K et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007; 58: 41113.
  • 5
    De Pas TM, Giovannini M, Manzotti M et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J. Clin. Oncol. 2011; 29: e819822.